Chimiothérapie néoadjuvante à base de cisplatine du cancer de la vessie : bientôt dépassée ? [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]

Détails

ID Serval
serval:BIB_3BB8FA781224
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Chimiothérapie néoadjuvante à base de cisplatine du cancer de la vessie : bientôt dépassée ? [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]
Périodique
Revue medicale suisse
Auteur(s)
Bosshard P., Roth B.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
27/11/2019
Peer-reviewed
Oui
Volume
15
Numéro
673
Pages
2190-2194
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
For more than 30 years, cisplatin-based neoadjuvant chemotherapy (NAC) has been administered to patients with muscle-invasive bladder cancer (MIBC). However, the benefit is modest. With the advent of modern immunotherapies, new therapeutic strategies are also opening up to bladder cancer. Unfortunately, the initial results in the neoadjuvant context show a response rate of only 20-35 %. Other therapeutic strategies, such as Pan-FGFR inhibitors, do not show better response. Due to the high genetic variability of bladder cancer, a « one drug fits all » concept is not an ideal solution. Patient selection based on the probability of response appears to be a promising strategy to improve this modest benefit of each treatment. In this context, the NAC will also continue to play an important role.
Mots-clé
Chemotherapy, Adjuvant, Cisplatin/therapeutic use, Humans, Immunotherapy/trends, Neoadjuvant Therapy/trends, Neoplasm Invasiveness, Patient Selection, Urinary Bladder Neoplasms/drug therapy, Urinary Bladder Neoplasms/pathology
Pubmed
Création de la notice
08/01/2021 20:25
Dernière modification de la notice
09/01/2021 7:26
Données d'usage